Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05169658
Title Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Washington
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.